Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer

Cancer Research

Volumn 71, Issue 17, 2011, Pages 5838-5849

  Lamoureux, Francois ^a   Thomas, Christian ^a   Yin, Min Jean ^b   Kuruma, Hidetoshi ^a   Beraldi, Eliana ^a   Fazli, Ladan ^a   Zoubeidi, Amina ^a   Gleave, Martin E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 DEMETHOXYGELDANAMYCIN; 4 (6,6 DIMETHYL 4 OXO 3 TRIFLUOROMETHYL 4,5,6,7 TETRAHYDROINDAZOL 1 YL) 2 (4 HYDROXYCYCLOHEXYLAMINO)BENZAMIDE; ANDROGEN RECEPTOR; CASPASE 3; CLUSTERIN; CUSTIRSEN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; KI 67 ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PF 04928473; PF 04929113; PRODRUG; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; UNCLASSIFIED DRUG; VINCULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CASTRATE RESISTANT PROSTATE CANCER; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL NUCLEUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIZATION; GENE; HEAT SHOCK PROTEIN 27 GENE; HEAT SHOCK PROTEIN 70 GENE; HEAT SHOCK RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SURVIVAL RATE; TRANSACTIVATION; TRANSCRIPTION REGULATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BENZAMIDES; BENZOQUINONES; CELL LINE, TUMOR; CLUSTERIN; DRUG SYNERGISM; HEAT-SHOCK RESPONSE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INDAZOLES; LACTAMS, MACROCYCLIC; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; THIONUCLEOTIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052256577     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0994     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990;50:3748-53. (Pubitemid 20194126)
3. Gleave ME, Bruchovsky N, Moore MJ, Venner P. Prostate cancer: 9. Treatment of advanced disease. Can Med Assoc J 1999;160:225-32. (Pubitemid 29060375)
4. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009;15:4792-8.
5. Miyake H, Nelson C, Rennie PS, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 30-kinase pathway. Endocrinology 2000;141:2257-65. (Pubitemid 32274381)
6. Culig Z. Androgen receptor cross-talk with cell signalling pathways. Growth Factors 2004;22:179-84. (Pubitemid 39377910)
7. Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999;5:2891-8. (Pubitemid 29493968)
8. Miyake H, Tolcher A, Gleave ME. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res 1999;59:4030-4. (Pubitemid 29393573)
9. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004;64:6595-602. (Pubitemid 39297919)
10. Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000;60:170-6. (Pubitemid 30058748)
11. Young JC, Hartl FU. Polypeptide release by Hsp90 involves ATP hydrolysis and is enhanced by the co-chaperone p23. EMBO J 2000;19:5930-40.
12. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-10. (Pubitemid 37187270)
13. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72. (Pubitemid 41400776)
14. Takayama S, Reed JC, Homma S. Heat-shock proteins as regulators of apoptosis. Oncogene 2003;22:9041-7. (Pubitemid 38121704)
15. Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, Neckers L.17AAG: low target binding affinity and potent cell activity-finding an explanation. Mol Cancer Ther 2003;2:123-9.
16. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002;8:986-93. (Pubitemid 34517631)
17. Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 2010;16:1088-93.
18. Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 1999;274:6875-81.
19. Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C, et al. Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 1997;3:1707-11. (Pubitemid 27444708)
20. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002;50:179-88. (Pubitemid 34137445)
21. Song H, Zhang B, Watson MA, Humphrey PA, Lim H, Milbrandt J. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Oncogene 2009;28:3307-19.
22. Miyake H, Nelson C, Rennie PS, Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone- repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 2000;60:2547-54. (Pubitemid 30262451)
23. Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2000;6:1655-63. (Pubitemid 30305057)
24. Gleave M, Chi KN. Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers. Ann N Y Acad Sci 2005;1058:1-15.
25. Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, et al. Clusterin knockdown using the antisense oligonucleotide OGX- 011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int 2008;102:389-97. (Pubitemid 352019195)
26. Leung SY, Jackson J, Miyake H, Burt H, Gleave ME. Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptoticregression of androgen-independent LNCaP prostate tumors. Prostate 2000;44:156-63. (Pubitemid 30419190)
27. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
28. Lamoureux F, Thomas C, Yin M, Kuruma H, Fazli L, Gleave ME, et al. A novel HSP90 inhibitor delays castrate resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res 2011;17:2301-13.
29. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008;68:2850-60. (Pubitemid 351556284)
30. Banerji U, de Bono J, Judson I, Kaye S, Workman P. Biomarkers in early clinical trials: the committed and the skeptics. Clin Cancer Res 2008;14:2512; author reply 2513-4.
31. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007;1113:202-16. (Pubitemid 350015011)
32. Zellweger T, Kiyama S, Chi K, Miyake H, Adomat H, Skov K, et al. Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU Int 2003;92:463-9. (Pubitemid 37100531)
33. Gleave ME, Monia BP. Antisense therapy for cancer. Nat Rev Cancer 2005;5:468-79. (Pubitemid 40791489)
34. Dai C, Whitesell L, Rogers AB, Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007;130: 1005-18. (Pubitemid 47410269)
35. Guo F, Rocha K, Bali P, Pranpat M, Fiskus W, Boyapalle S, et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17- allylamino-demethoxy geldanamycin. Cancer Res 2005;65:10536-44. (Pubitemid 41743748)
36. Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 2008;14:240-8. (Pubitemid 351378001)
37. Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, Huang K, et al. SNX- 2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 2009;113:846-55.
38. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A 2006;103:17408-13. (Pubitemid 44788982)
39. Cervantes-Gomez F, Nimmanapalli R, Gandhi V. Transcription inhibition of heat shock proteins: a strategy for combination of 17-allylamino- 17-demethoxygeldanamycin and actinomycin d. Cancer Res 2009;69:3947-54.
40. Bagatell R, Paine-Murrieta GD, Taylor CW, Pulcini EJ, Akinaga S, Benjamin IJ, et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 2000;6:3312-8. (Pubitemid 30637762)
41. Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995;27:633-45.
42. Kyprianou N, English HF, Davidson NE, Isaacs JT. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 1991;51:162-6.
43. Miyake H, Hara S, Zellweger T, Kamidono S, Gleave ME, Hara I. Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cells. Mol Urol 2001;5:105-11. (Pubitemid 32848102)
44. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 20-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005; 97:1287-96. (Pubitemid 41535369)
45. Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, et al. A phase I study of OGX-011, a 20-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008;14:833-9. (Pubitemid 351231167)
46. Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:4247-54.
47. Georget V, Terouanne B, Nicolas JC, Sultan C. Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry 2002;41:11824-31.
48. Kim J, Coetzee GA. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem 2004;93:233-41. (Pubitemid 44264201)
49. Rossi A, Ciafre S, Balsamo M, Pierimarchi P, Santoro MG. Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer. Cancer Res 2006;66:7678-85. (Pubitemid 44289226)
50. Glaze ER, Lambert AL, Smith AC, Page JG, Johnson WD, McCormick DL, et al. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)- 17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer Chemother Pharmacol 2005;56:637-47. (Pubitemid 41425061)